Regeneron and Sanofi's Dupixent shows treatment effect in mid-stage eosinophilic esophagitis study

Published 10/16/2017, 12:06 PM
© Reuters.  Regeneron and Sanofi's Dupixent shows treatment effect in mid-stage eosinophilic esophagitis study
SASY
-
SNY
-
REGN
-
  • Results from a Phase 2 clinical trial assessing Regeneron Pharmaceuticals (REGN +0.7%) and Sanofi (PA:SASY)'s (SNY +0.7%) DUPIXENT (dupilumab) in adult patients with moderate-to-severe eosinophilic esophagitis (EE) showed a treatment benefit. The data were presented at the World Congress of Gastroenterology in Orlando, FL.
  • The primary endpoint was a scale of swallowing difficulty called SDI score. At week 10, patients receiving dupilumab reported a significant improvement in the ability to swallow as measured by a three-point reduction (45% improvement) in SDI score, much better than placebo's 19% improvement (1.3-point reduction in SDI score) (p=0.0304).
  • Dupilumab has Orphan Drug status for EE. It was approved in May for eczema.
  • Now read: Sanofi: Upward Trajectory In 2017


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.